Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Total Non-Current Liabilities (2023 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $66.2 million as the latest value for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 16.52% year-over-year to $66.2 million; the TTM value through Dec 2025 reached $66.2 million, down 16.52%, while the annual FY2025 figure was $66.2 million, 16.52% down from the prior year.
  • Total Non-Current Liabilities was $66.2 million for Q4 2025 at Day One Biopharmaceuticals, up from $62.2 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $79.3 million in Q4 2024, with the low at $29.5 million in Q4 2023.
  • Historically, Total Non-Current Liabilities has averaged $58.1 million across 3 years, with a median of $59.8 million in 2025.
  • The largest annual shift saw Total Non-Current Liabilities skyrocketed 168.66% in 2024 before it dropped 16.52% in 2025.
  • Over 3 years, Total Non-Current Liabilities stood at $29.5 million in 2023, then skyrocketed by 168.66% to $79.3 million in 2024, then dropped by 16.52% to $66.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $66.2 million in Q4 2025, $62.2 million in Q3 2025, and $57.4 million in Q2 2025.